Formulation optimization, skin irritation, and efficacy characterization of a novel skin-lightening agent

Journal of Cosmetic Dermatology

Volumn 11, Issue 2, 2012, Pages 101-110

  Jain, Piyush ^a   Sonti, Sujatha ^b   Garruto, John ^b   Mehta, Rahul ^b   Banga, Ajay K ^a  

^a MERCER UNIVERSITY   (United States)

^b SkinMedica Inc   (United States)

Author keywords

Intradermal delivery; Pigmented skin equivalents; Skin irritation; Skin lightener; Skin permeation

Indexed keywords

ALCOHOL; BLEACHING AGENT; DIETHYLENE GLYCOL MONOETHYL ETHER; ISOSORBIDE DERIVATIVE; MELANIN; PENETRATION ENHANCING AGENT; SKIN LIGHTENING AGENT; SMA 012; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MELANOGENESIS; NONBIOLOGICAL MODEL; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN IRRITATION; SKIN PERMEABILITY;

ALKALOIDS; BLEACHING AGENTS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DERMATITIS, CONTACT; ETHANOL; ETHYLENE GLYCOLS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERPIGMENTATION; ISOSORBIDE; MELANINS; MELANOCYTES; MODELS, BIOLOGICAL; PERMEABILITY; SKIN; SKIN PHYSIOLOGICAL PHENOMENA;

EID: 84861922153     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2012.00610.x     Document Type: Article

References (24)

1. Monteiro-Riviere NA, Inman AO, Snider TH et al. Comparison of an in vitro skin model to normal human skin for dermatological research. Microsc Res Tech 1997; 37: 172-9.
2. Loefler IJ. Pigmentation, melanocortins and red hair. QJM 1999; 92: 418-19.
3. Ortonne JP, Bissett DL. Latest insights into skin hyperpigmentation. J Investig Dermatol Symp Proc 2008; 13: 10-14.
4. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 2006; 19: 550-71.
5. Taylor A, Pawaskar M, Taylor SL et al. Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. J Cosmet Dermatol 2008; 7: 164-8.
6. Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin 2005; 23: 209-26.
7. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 2003; 42: 966-72.
8. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004; 74: 362-8.
9. Chang J, Rocha A, Inventors. Medicated toning lotion. U.S. Patent (US2010/0233107). Sep. 16, 2010.
10. Gura T. Toxicity testing moves from the legislature to the petri dish-and back. Cell 2008; 134: 557-9.
11. McDonnell-Phillip JJ. Deratologic product testing, part 1. Transdermal Magazine 2010; 2: 14-17.
12. Kandarova H, Hayden P, Klausner M et al. In vitro skin irritation testing: improving the sensitivity of the EpiDerm skin irritation test protocol. Altern Lab Anim 2009; 37: 671-89.
13. Kandarova H, Hayden P, Klausner M et al. An in vitro skin irritation test (SIT) using the EpiDerm reconstructed human epidermal (RHE) model. J Vis Exp 2009; [Accessed on March 23, 2012].
14. Wang Z, Li X, Yang Z et al. Effects of aloesin on melanogenesis in pigmented skin equivalents. Int J Cosmet Sci 2008; 30: 121-30.
15. Takeyama R, Takekoshi S, Nagata H et al. Quercetin-induced melanogenesis in a reconstituted three-dimensional human epidermal model. J Mol Histol 2004; 35: 157-65.
16. Klausner M, Neal P, Hayden P, Kubilus J. Use of melanoderm, an epidermal model containing functional melanocytes, for skin pigmentation studies. J Investig Dermatol 2000; 114: 859. (Abstr.).
17. Jones K, Hughes J, Hong M et al. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res 2002; 15: 335-40.
18. Choo SJ, Ryoo IJ, Kim YH et al. Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol 2009; 61: 663-7.
19. Otto A, Wiechers JW, Kelly CL et al. Effect of penetration modifiers on the dermal and transdermal delivery of drugs and cosmetic active ingredients. Skin Pharmacol Physiol 2008; 21: 326-34.
20. Godwin DA, Kim NH, Felton LA. Influence of Transcutol CG on the skin accumulation and transdermal permeation of ultraviolet absorbers. Eur J Pharm Biopharm 2002; 53: 23-7.
21. Banks S, Pinninti R, Gill H et al. Flux Across Microneedle-treated Skin is Increased by Increasing Charge of Naltrexone and Naltrexol <b><i>In Vitro</i></b>. Pharm Res 2008; 25: 1964.
22. Leichtnam ML, Rolland H, Wuthrich P, Guy RH. Enhancement of transdermal testosterone delivery by supersaturation. J Pharm Sci 2006; 95: 2373-9.
23. Moser K, Kriwet K, Froehlich C et al. Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug. Pharm Res 2001; 18: 1006-11.
24. Barichello JM, Handa H, Kisyuku M et al. Inducing effect of liposomalization on the transdermal delivery of hydrocortisone: creation of a drug supersaturated state. J Control Release 2006; 115: 94-102.